TerminatedNot Applicable

Early Biomarkers of Tumor Response in High Dose Hypofractionated Radiotherapy Word Package 3 : Immune Response

Stopped: Lack of patient enrollment

France28 participantsStarted 2015-09-16

Plain-language summary

This study will follow-up immune cell populations, secreted factors and released nanovesicles in the blood before, during and after high dose radiation therapy which should give new information of the efficacy of the hypofractionated high dose radiation therapy and a rationale for adjuvant immunotherapy.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patient requiring a hypofractionated irradiation (≥ 3 fractions, dose ≥ 9 Gy per fraction) either for : * hepatocellular carcinoma or hepatic lesion of metastatic Colorectal Cancer, * metastasis from melanoma or renal cancer, * Age ≥ 18 years old, * Registered with a social security system, * Signed written informed consent. Exclusion Criteria: * Patient treated by chemotherapy, targeted or immunotherapy within 21 days before the first sampling, * Pregnant or breastfeeding woman, * Patient under guardianship or tutorship.

What they're measuring

Analyse of immunological parameters, decription of secreted markers and nanovesicles production

Timeframe: from baseline to 1 year follow up

Trial details

NCT IDNCT02439008

SponsorCentre Oscar Lambret

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2018-06-21

View on ClinicalTrials.gov More Carcinoma, Hepatocellular trials